Embora o paracetamol profilático seja geralmente administrado de modo rotineiro para prevenir reações transfusionais febris não hemolíticas, há poucas evidências na literatura para dar suporte a essa prática.[4]Laureano M, Khandelwal A, Yan M. Canadian Blood Services. Clinical guide to transfusion: transfusion reactions (chapter 10). Oct 2022 [internet publication].
https://professionaleducation.blood.ca/en/transfusion/clinical-guide/transfusion-reactions
[17]Tobian AA, King KE, Ness PM. Transfusion premedications: a growing practice not based on evidence. Transfusion. 2007 Jun;47(6):1089-96.
http://www.ncbi.nlm.nih.gov/pubmed/17524101?tool=bestpractice.com
[52]Geiger TL, Howard SC. Acetaminophen and diphenhydramine premedication for allergic and febrile nonhemolytic transfusion reactions: good prophylaxis or bad practice? Transfus Med Rev. 2007 Jan;21(1):1-12.
http://www.ncbi.nlm.nih.gov/pubmed/17174216?tool=bestpractice.com
A leucorredução pré-armazenamento demonstrou reduzir significativamente a incidência de reações transfusionais febris não hemolíticas.[1]Soutar R, McSporran W, Tomlinson T, et al. Guideline on the investigation and management of acute transfusion reactions. Br J Haematol. 2023 Jun;201(5):832-44.
https://onlinelibrary.wiley.com/doi/10.1111/bjh.18789
http://www.ncbi.nlm.nih.gov/pubmed/37211954?tool=bestpractice.com
[6]American Red Cross. A compendium of transfusion practice guidelines: fourth edition. 2021 [internet publication].
https://www.redcrossblood.org/content/dam/redcrossblood/rcb/biomedical-services/components/compendium_v_4.0.pdf
[53]Blajchman MA. The clinical benefits of the leukoreduction of blood products. J Trauma. 2006 Jun;60(6 Suppl):S83-90.
http://www.ncbi.nlm.nih.gov/pubmed/16763486?tool=bestpractice.com
Em muitos países, a leucorredução universal do suprimento de sangue foi implementada.
A pré-medicação com anti-histamínicos geralmente é administrada para prevenir reações alérgicas., mas existem poucas evidências na literatura para dar suporte a essa prática.[1]Soutar R, McSporran W, Tomlinson T, et al. Guideline on the investigation and management of acute transfusion reactions. Br J Haematol. 2023 Jun;201(5):832-44.
https://onlinelibrary.wiley.com/doi/10.1111/bjh.18789
http://www.ncbi.nlm.nih.gov/pubmed/37211954?tool=bestpractice.com
[17]Tobian AA, King KE, Ness PM. Transfusion premedications: a growing practice not based on evidence. Transfusion. 2007 Jun;47(6):1089-96.
http://www.ncbi.nlm.nih.gov/pubmed/17524101?tool=bestpractice.com
[52]Geiger TL, Howard SC. Acetaminophen and diphenhydramine premedication for allergic and febrile nonhemolytic transfusion reactions: good prophylaxis or bad practice? Transfus Med Rev. 2007 Jan;21(1):1-12.
http://www.ncbi.nlm.nih.gov/pubmed/17174216?tool=bestpractice.com
[54]Martí-Carvajal AJ, Solà I, González LE, et al. Pharmacological interventions for the prevention of allergic and febrile non-haemolytic transfusion reactions. Cochrane Database Syst Rev. 2010 Jun 16;6:CD007539.
http://www.ncbi.nlm.nih.gov/pubmed/20556779?tool=bestpractice.com
Entretanto, a pré-medicação com difenidramina pode ser útil em pacientes com história de reações alérgicas recorrentes moderadas ou graves à transfusão.[1]Soutar R, McSporran W, Tomlinson T, et al. Guideline on the investigation and management of acute transfusion reactions. Br J Haematol. 2023 Jun;201(5):832-44.
https://onlinelibrary.wiley.com/doi/10.1111/bjh.18789
http://www.ncbi.nlm.nih.gov/pubmed/37211954?tool=bestpractice.com
A transfusão de componentes lavados nesses pacientes também deve ser considerada.[1]Soutar R, McSporran W, Tomlinson T, et al. Guideline on the investigation and management of acute transfusion reactions. Br J Haematol. 2023 Jun;201(5):832-44.
https://onlinelibrary.wiley.com/doi/10.1111/bjh.18789
http://www.ncbi.nlm.nih.gov/pubmed/37211954?tool=bestpractice.com
[21]Mazzei CA, Popovsky MA, Kopko PM. Noninfectious complications of blood transfusion. In: Roback JD, Combs MR, Grossman BJ, et al., eds. Technical Manual, 16th Ed. Bethesda, MD: American Association of Blood Banks; 2008:715-49.
As transfusões de plasma para pacientes com conhecida deficiência de imunoglobulina A (IgA; e que produzem anticorpos anti-IgA) devem ter origem de doadores deficientes em IgA.[6]American Red Cross. A compendium of transfusion practice guidelines: fourth edition. 2021 [internet publication].
https://www.redcrossblood.org/content/dam/redcrossblood/rcb/biomedical-services/components/compendium_v_4.0.pdf
[21]Mazzei CA, Popovsky MA, Kopko PM. Noninfectious complications of blood transfusion. In: Roback JD, Combs MR, Grossman BJ, et al., eds. Technical Manual, 16th Ed. Bethesda, MD: American Association of Blood Banks; 2008:715-49. Eritrócitos e plaquetas devem passar por uma lavagem pré-transfusão, o que efetivamente remove as proteínas plasmáticas.[1]Soutar R, McSporran W, Tomlinson T, et al. Guideline on the investigation and management of acute transfusion reactions. Br J Haematol. 2023 Jun;201(5):832-44.
https://onlinelibrary.wiley.com/doi/10.1111/bjh.18789
http://www.ncbi.nlm.nih.gov/pubmed/37211954?tool=bestpractice.com
[6]American Red Cross. A compendium of transfusion practice guidelines: fourth edition. 2021 [internet publication].
https://www.redcrossblood.org/content/dam/redcrossblood/rcb/biomedical-services/components/compendium_v_4.0.pdf
[21]Mazzei CA, Popovsky MA, Kopko PM. Noninfectious complications of blood transfusion. In: Roback JD, Combs MR, Grossman BJ, et al., eds. Technical Manual, 16th Ed. Bethesda, MD: American Association of Blood Banks; 2008:715-49.
Os pacientes com história de púrpura pós-transfusional devem receber componentes adicionais de doadores com antígenos compatíveis.[6]American Red Cross. A compendium of transfusion practice guidelines: fourth edition. 2021 [internet publication].
https://www.redcrossblood.org/content/dam/redcrossblood/rcb/biomedical-services/components/compendium_v_4.0.pdf
Isso deve ser realizado mediante consulta com um banco de sangue.[21]Mazzei CA, Popovsky MA, Kopko PM. Noninfectious complications of blood transfusion. In: Roback JD, Combs MR, Grossman BJ, et al., eds. Technical Manual, 16th Ed. Bethesda, MD: American Association of Blood Banks; 2008:715-49.
Os fatores de risco para a doença do enxerto contra o hospedeiro associada à transfusão incluem leucemia ou linfoma, tratamento com medicamentos imunossupressores, imunodeficiência congênita ou estado neonatal.[9]Foukaneli T, Kerr P, Bolton-Maggs PHB, et al. Guidelines on the use of irradiated blood components. Br J Haematol. 2020 Dec;191(5):704-24.
https://onlinelibrary.wiley.com/doi/10.1111/bjh.17015
http://www.ncbi.nlm.nih.gov/pubmed/32808674?tool=bestpractice.com
[55]Australian & New Zealand Society of Blood Transfusion. Guidelines for prevention of transfusion-associated graft-versus-host disease (TA-GVHD). Sydney, Australia: Australian & New Zealand Society of Blood Transfusion Ltd; 2011.
https://anzsbt.org.au/guidelines-standards/anzsbt-guidelines
Os pacientes devem receber componentes que foram irradiados antes da transfusão. A irradiação elimina os linfócitos responsáveis pela resposta imune mediada por célula que causa a doença do enxerto contra o hospedeiro.[9]Foukaneli T, Kerr P, Bolton-Maggs PHB, et al. Guidelines on the use of irradiated blood components. Br J Haematol. 2020 Dec;191(5):704-24.
https://onlinelibrary.wiley.com/doi/10.1111/bjh.17015
http://www.ncbi.nlm.nih.gov/pubmed/32808674?tool=bestpractice.com
[30]Dwyre DM, Holland PV. Transfusion-associated graft-versus-host disease. Vox Sang. 2008 Aug;95(2):85-93.
http://www.ncbi.nlm.nih.gov/pubmed/18544121?tool=bestpractice.com
A hipotermia está associada a transfusões de grande volume. Isso pode ser evitado com o aquecimento dos componentes sanguíneos.[4]Laureano M, Khandelwal A, Yan M. Canadian Blood Services. Clinical guide to transfusion: transfusion reactions (chapter 10). Oct 2022 [internet publication].
https://professionaleducation.blood.ca/en/transfusion/clinical-guide/transfusion-reactions
[50]Perrota PL, Snyder EL. Non-infectious complications of transfusion therapy. Blood Rev. 2001 Jun;15(6):69-83.
http://www.ncbi.nlm.nih.gov/pubmed/11409907?tool=bestpractice.com
Como os anticorpos leucocitários são muito mais prevalentes em doadores do sexo feminino que do masculino, uma estratégia para prevenir a lesão pulmonar aguda relacionada à transfusão (TRALI) é descartar as mulheres do conjunto de doadores de plasma.[4]Laureano M, Khandelwal A, Yan M. Canadian Blood Services. Clinical guide to transfusion: transfusion reactions (chapter 10). Oct 2022 [internet publication].
https://professionaleducation.blood.ca/en/transfusion/clinical-guide/transfusion-reactions
Desde que o Reino Unido começou a descartar o plasma de doadores do sexo feminino para transfusões em 2004, vários outros países também implementaram ou estão considerando a implementação desta política para a prevenção da TRALI.[56]Middelburg RA, van Stein D, Zupanska B, et al. Female donors and transfusion-related acute lung injury. Transfusion. 2010 Nov;50(11):2447-54.
http://www.ncbi.nlm.nih.gov/pubmed/20529001?tool=bestpractice.com
Embora a eficácia desta política não tenha sido comprovada, ela é suportada por revisões sistemáticas recentes.[57]Schmickl CN, Mastrobuoni S, Filippidis FT, et al. Male-predominant plasma transfusion strategy for preventing transfusion-related acute lung injury: a systematic review. Crit Care Med. 2015 Jan;43(1):205-25.
http://www.ncbi.nlm.nih.gov/pubmed/25514705?tool=bestpractice.com
[58]Müller MC, van Stein D, Binnekade JM, et al. Low-risk transfusion-related acute lung injury donor strategies and the impact on the onset of transfusion-related acute lung injury: a meta-analysis. Transfusion. 2015 Jan;55(1):164-75.
http://www.ncbi.nlm.nih.gov/pubmed/25135630?tool=bestpractice.com
[59]Chassé M, McIntyre L, English SW, et al. Effect of blood donor characteristics on transfusion outcomes: a systematic review and meta-analysis. Transfus Med Rev. 2016 Feb 9;30(2):69-80.
https://www.sciencedirect.com/science/article/pii/S0887796315300079?via%3Dihub
http://www.ncbi.nlm.nih.gov/pubmed/26920039?tool=bestpractice.com